GlassScriptPhysician profile
Alexander Young
NPI 1770081648
$1,083.66
in general payments reported to CMS, 2019-2025
9 companies · $56.85 in 2025
The $56.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $257 · 2023: $392 · 2024: $90.99 · 2025: $56.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $370.41 | 2021-2024 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $343.92 | 2021-2024 | |
| Abbott Laboratories | $178.72 | 2021-2024 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.88 | 2022-2024 | Lifevest |
| Pfizer INC. | $35.16 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $35.08 | 2025 | Onpattro |
| Cvrx, INC. | $28.62 | 2023 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $22.10 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.77 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.